[Which calcium antagonists for hypertension?]
1Clinique d'Hypertension Artérielle, Hôpital Erasme, U.L.B.
Insights
Long-acting calcium antagonists are safe and effective for cardiovascular disease treatment. Evidence does not support concerns raised by older studies on short-acting versions, particularly regarding cardiac events.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Calcium antagonists have been utilized for over 25 years in managing cardiovascular diseases.
- Recent retrospective studies raised concerns about short-acting dihydropyridines, linking them to increased cardiac events, cancer, and gastrointestinal bleeding.
Purpose:
- To evaluate the safety and efficacy of calcium antagonists, particularly newer long-acting formulations, in cardiovascular disease treatment.
- To address conflicting findings between retrospective and prospective studies regarding calcium antagonist use.
Summary:
- Randomized prospective studies have not confirmed the adverse event incidence suggested by retrospective analyses of short-acting dihydropyridines.
- Studies involving verapamil and diltiazem indicate potential benefits in cardiovascular mortality and morbidity for hypertensive patients.
- Current evidence does not support extrapolating negative findings from short-acting calcium antagonists to the newer long-acting generations.
Impact:
- Provides a clearer understanding of the safety profile of modern calcium antagonists.
- Informs clinical practice regarding the appropriate use of calcium antagonists in cardiovascular disease management.
- Highlights the importance of differentiating between drug formulations and study designs when assessing therapeutic outcomes.
Abstract:
Calcium antagonists have been used for treatment of cardiovascular diseases for more than 25 years. Several recent retrospective studies have suggested that chronic treatment with short-acting dihydropyridines increased the incidence of cardiac events, cancer and gastrointestinal bleedings. Randomized prospective studies have, however, never been able to confirm these observations. In addition, well-conducted studies using verapamil and diltiazem have suggested that these calcium antagonists may even improve cardiovascular mortality and morbidity of the hypertensive patient. There is therefore no reason to believe that the questionable results derived from retrospective studies of the effects of short-acting calcium antagonists on cardiac and noncardiac events may apply to the newer generation of long-acting calcium antagonists.
Related Concept Videos
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications
01:18Antihypertensive Drugs: Action of Calcium Channel Blockers
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:17Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...